Compare Adaptive Biotechnologies Corp (ADPT) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cenovus Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.98 (market cap $3.33B), while Cenovus Energy Inc trades at $26.35 (market cap $47.02B). The key difference: Cenovus Energy Inc is far larger — about 14.1× Adaptive Biotechnologies Corp's market cap, and Cenovus Energy Inc pays a 2.46% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CVE | |
|---|---|---|
Market Cap | $3.33B | $47.02B |
Sector | Health | Energy |
52-Week High | $22.37 | $31.80 |
52-Week Low | $10.24 | $13.96 |
Enterprise Value | $3.19B | $54.90B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Cenovus Energy (CVE) trades at $25.21, up 2.27% with a bearish technical signal. Recent earnings beats and an attractive P/E of 13.78 highlight fundamental strength, while cash flow trends show operational resilience despite negative net flows. The company maintains a solid balance sheet with a debt-to-asset ratio of 13.63% as of 2024.
CVE offers value with low valuation multiples and consistent profitability, but faces headwinds from volatile oil prices and regulatory challenges. Analyst consensus is mixed with 40.74% buy ratings, suggesting cautious optimism for long-term growth amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
